All In MedTech

Device Trial Radar · NCT07556809

Exoskeleton Gait Training in Guillain-Barré Syndrome: Safety, Feasibility, Usability, and Longitudinal Outcomes

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Aug 7, 2023

Primary completion

Dec 12, 2025

Study completion Dec 12, 2025

Sponsor

Lead sponsor
Institut GuttmannAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wandercraft
First posted
Apr 29, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to determine if the Atalante X exoskeleton by Wandercraft is a safe, reliable, and usable device for people with Guillain-Barré Syndrome (GBS) who are unable to walk. The secondary objective is to assess the impact of using this device on the gait and functional recovery of this type of users (GBS). The users undergo 20 training sessions over 6 weeks. Assessments are carried out at baseline, post-intervention, and at a 4-week follow-up after completing the training sessions. In all assessments, the same outcomes is conducted using the Medical Research Council Outcome, 10-Meter Walk Test, 6-Minute Walking Test, Kansas University Standing Balance Scale, Functional Independence Measure and Level of Assistence. To assess satisfaction, the QUEST 2.0 scale is administered. During this 20 sessions, monitoring is conducted for possible adverse effects that may appear and for the time required for donning and doffing the device.

Conditions

  • Guillain Barré Syndrome

Interventions

  • Exoskeleton Wandercraft Atalante X, usability and gait rehabilitationDevice

    Exoskeleton Wandercraft Atalante X trainning in Guillain Barre syndrome

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety deviceTime frame: From baseline to the Week 6(end of intervention).
  2. FesabilityTime frame: From baseline to the Week 6 (end of intervention).
  3. Usability and satisfactionTime frame: From baseline to the week 3 (10 session).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut Guttmann

    Badalona, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.